Additional information
by Richard C. Zink (Author)
International guidelines recommend that clinical trial data should be actively reviewed or monitored; the well-being of trial participants and the validity and integrity of the final analysis results are at stake. Risk-based monitoring (RBM) makes use of central computerized review of clinical trial data and site metrics to determine if and when clinical sites should receive more extensive quality review or intervention. Risk-Based Monitoring and Fraud Detection in Clinical Trials Using JMP and SAS describes analyses for RBM that incorporate and extend the recommendations of TransCelerate Biopharm Inc., methods to detect potential patient-or investigator misconduct, snapshot comparisons to more easily identify new or modified data, and other novel visual and analytical techniques to enhance safety and quality reviews. The analytical methods described enable the clinical trial team to take a proactive approach to data quality and safety to streamline clinical development activities and address shortcomings while the study is ongoing.
Author Biography
Richard C. Zink is a Principal Research Statistician Developer in the JMP Life Sciences division at SAS Institute. He is a developer for JMP Clinical, an innovative software package designed to streamline the review of clinical trial data. He joined SAS in 2011 after eight years in the pharmaceutical industry, where he designed and analyzed clinical trials for patients diagnosed with chronic hepatitis B infection, chronic myeloid leukemia, glaucoma, dry eye disease, blepharitis, or cystic fibrosis; he also participated in US and European drug submissions and in two FDA advisory committee hearings. When not actively engaged in clinical development responsibilities, he supported non-clinical development, pharmaceutical sciences, and sales and marketing activities. Richard is a member of the Biopharmaceutical Section of the American Statistical Association, the Drug Information Association, and Statisticians in the Pharmaceutical Industry. He is currently the Statistics Section Editor for Therapeutic Innovation & Regulatory Science (formerly Drug Information Journal). His research interests include the analysis of pre- and post-market adverse events, subgroup identification for patients with enhanced treatment response, and risk-based monitoring and fraud detection in clinical trials. Richard holds a Ph.D. in Biostatistics from the University of North Carolina at Chapel Hill and has more than 20 years of SAS programming experience. This is his first book.
